ERBB2 and neoplasm: The adverse prognostic factors are age ≥50–60, tumor size ≥ 3 cm, poor differentiation, Ki-67 labeling index ≥10%, SUVmax > 6.5, HER-2/neu immunostaining and amplification, PD-L1-positive, lymph node metastases, and distant metastases.